Ammon S et al. |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848660
|
Leiper K et al. |
Open label trial of oral clarithromycin in active Crohn's disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848665
|
Sharara AI et al. |
Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238584
|
Graham DY and Gisbert JP |
Letter: clarithromycin dose for H. pylori therapy remains unresolved. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238583
|
Kositchaiwat C et al. |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616168
|
Romero-Gómez M et al. |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616169
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Dalla Libera M et al. |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8730251
|
Labenz J et al. |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8730252
|
Murakami K et al. |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12390102
|
Lamouliatte H et al. |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535872
|
Miehlke S et al. |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535873
|
Bühling A et al. |
Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11552917
|
Neri M et al. |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535876
|
Dani R et al. |
Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10594400
|
Lehmann FS et al. |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735923
|
Miwa H et al. |
Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735925
|
Spinzi GC et al. |
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735926
|
Graham DY et al. |
Furazolidone combination therapies for Helicobacter pylori infection in the United States. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651662
|
Wong BC et al. |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651663
|
Harris AW et al. |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7605863
|
Katelaris PH et al. |
A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7605864
|
Malfertheiner P et al. |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969088
|
Hassan C et al. |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969091
|
Sheu BS et al. |
Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856088
|
Malfertheiner P et al. |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860399
|
Huang J and Hunt RH |
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383500
|
Barth J and Hahne W |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849125
|
Miwa H et al. |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383502
|
Ducóns JA et al. |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383507
|
Calvet X et al. |
Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383508
|
Sieg A et al. |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383519
|
Cestari R |
Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798804
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Gisbert JP and Calvet X |
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21745241
|
Leiper K et al. |
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18315579
|
Spadaccini A et al. |
Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8899094
|
Thung I et al. |
Review article: the global emergence of Helicobacter pylori antibiotic resistance. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26694080
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Savarino V et al. |
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9305478
|
Williams MP et al. |
Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9305479
|
Broutet N et al. |
Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492738
|
Higuchi K et al. |
Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492739
|
Coelho LG et al. |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492742
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Zullo A et al. |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17539982
|
Zamani M et al. |
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074507
|
Laine L and Dhir V |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030957
|
Vallve M et al. |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030958
|
Colin R |
Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030959
|